Full Press Release Details
Rigor Needed To Harness Innovation For Growth
Keep up with the top pharma business news of the week. On the go.
Scrip brings you a weekly bulletin of top picks.
FDMT Neutral Sentiment
Scrip Asks… What Does 2025 Hold For Biopharma? Part 1: The State Of The Biopharma Industry
Key Takeaway: The article discusses the current state of the biopharma industry and anticipates what 2025 may hold for it. It emphasizes the need for rigor in harnessing innovation to drive growth. The content is part of a series from Scrip that aims to provide insights into the biopharma sector.
Price reaction · baseline $4.76 (2025-01-13 close) · hit pre-market · 1 other FDMT headline(s) in the window, move may be shared
day 0 close · peak
+2.5%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+128%
120-day peak, hindsight
Typical move
11.2%
average across 9 past catalysts
Cash runway
~18 mo
Low dilution risk
Lead asset
4D-150 IVT
Phase 3 · Macular Neovascularization Secondary to Age-Related Macular Degeneration